drugset / Trial / NCT04507503

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04507503

Expanded access Approved for marketing Taiho Oncology, Inc.

Summary

The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Futibatinib Small molecule 20 mg Oral

Indications